Tirzepatide
Dual GIP/GLP-1 metabolic protocol
$738 billed per 3-month shipment · cancel anytime
Dual-agonist therapy for patients who need stronger metabolic support. Eligibility is determined during physician review.
Final strength is set by your prescribing physician and may differ from your request.
Prescription required. A Vmed physician reviews your intake before anything is dispensed — you're not charged until approval.
Filled by a licensed 503A compounding pharmacy and shipped cold-chain.
What's included
- Dual GIP + GLP-1 mechanism
- Quarterly lab monitoring included
- Adjusts with your response, not a fixed ladder
- Pause or cancel your subscription anytime
Protocol details
- Route
- Subcutaneous injection
- Cadence
- Once weekly
- Vial
- 10 mg/mL multi-dose vial
- Dispensed by
- 503A compounding pharmacy
- Ships
- Cold-chain, 2-day, refrigerated
Clinical summary
Dual GIP and GLP-1 receptor agonist, producing greater average appetite suppression and glycemic effect than GLP-1 alone.
Typical course: 16–20 weeks of titration, then ongoing maintenance.
Common side effects: Nausea, Diarrhea, Reduced appetite, Injection-site reaction.
You may not be eligible if
- · Personal or family history of medullary thyroid carcinoma
- · MEN2 syndrome
- · Pregnant, nursing or planning pregnancy
- · Severe gastroparesis
This is not medical advice. Your physician makes the final determination during review. Compounded medications are not FDA-approved.